Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on May 4, 2021. The report discloses a material corporate event occurring on the same date regarding a planned public offering of common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notice of a corporate transaction rather than a financial performance report.
Material Changes
On May 4, 2021, the Company entered into an Underwriting Agreement with H.C. Wainwright & Co., LLC. This agreement facilitates a registered public offering of the Company's common stock.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the underwriting agreement. The filing does not contain specific financial guidance, risk factors, or contingencies related to the offering terms within the body of this report; details are referenced in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the specific terms of the Underwriting Agreement with H.C. Wainwright & Co., LLC.
- Review the attached Press Release (Exhibit 99.1) for the number of shares to be offered and the offering price.
- Confirm the intended use of proceeds from the registered public offering.
- Check for any lock-up agreements or underwriting discounts disclosed in the full prospectus.